Investment Rating - The report initiates coverage with a "Buy" rating for Xiaomi Group (1810.HK) [6] Core Insights - The company is positioned as a rare platform that has scaled in three major sectors: global smartphones, consumer AIoT, and smart electric vehicles. As of Q4 2025, Xiaomi ranks among the top three in global smartphone shipments for 22 consecutive quarters, with a projected market share of 13.3% by 2025. The AIoT platform is expected to connect 1.08 billion devices by the end of 2025, establishing a leading position in the consumer IoT market. The automotive segment is projected to deliver 411,000 vehicles in 2025, with strong early demand for the new Xiaomi SU7 model [6][10][12]. Financial Data and Profit Forecast - Total revenue projections (in million CNY) for Xiaomi Group are as follows: - 2024: 365,906.35 - 2025: 457,286.69 - 2026E: 539,450.02 - 2027E: 656,374.58 - 2028E: 801,697.62 - Year-on-year growth rates are expected to be 35.04% for 2024, 24.97% for 2025, and 17.97% for 2026 [5][18]. - Net profit projections (in million CNY) are: - 2024: 23,658.13 - 2025: 41,643.39 - 2026E: 33,830.95 - 2027E: 43,178.52 - 2028E: 54,244.52 - The report anticipates a significant increase in net profit for 2025, with a year-on-year growth rate of 76.02% [5][18]. Business Segments and Valuation - The report estimates that by 2026, the mobile and AIoT business will generate revenue of 375 billion CNY, with a net profit of 31.9 billion CNY. The automotive and AI innovation business is expected to generate 164.4 billion CNY in revenue, with a net profit of 3.3 billion CNY. The valuation method applied is a sum-of-the-parts (SOTP) approach, assigning a PE of 20x for the mobile and AIoT business and a PS of 1.5x for the automotive segment [16][18]. - The target total market capitalization for 2026 is estimated at approximately 10,018 billion HKD, representing an upside potential of 19% from the current market value [6][16]. Key Assumptions - Revenue growth is driven by strong performance in the automotive sector, with expected growth rates of 55%, 50%, and 40% for the automotive business from 2026 to 2028. The report identifies 2026 as a pivotal year for the company, marking a transition to a more profitable phase as the automotive scale effects become evident [6][12]. Catalysts - Key catalysts for growth include the successful launch of new automotive models, expansion in overseas markets, and advancements in AI technology. The report emphasizes the importance of monitoring order conversion rates for the new SU7 model and the company's progress in international markets [6][12].

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company experienced a significant increase in gold production and prices, leading to a substantial growth in net profit by 293% in 2025. The total revenue for 2025 reached HKD 2.4 billion, a year-on-year increase of 49.8%, with net profit attributable to shareholders amounting to HKD 830 million [1][9] - The increase in revenue was primarily driven by a rise in the average selling price of gold from RMB 540 per gram in 2024 to RMB 747 per gram in 2025, alongside an increase in gold sales volume from approximately 2.22 tons in 2024 to about 2.96 tons in 2025 [2][10] - The company maintained a gross profit margin of 54.7% in 2025, up from 40.1% in 2024, attributed to effective cost control and the rise in gold prices [2][10] Financial Performance Summary - In 2025, the company's cash costs slightly increased from RMB 283 per gram in 2024 to RMB 306 per gram in 2025, while the all-in sustaining costs rose from RMB 368 per gram to RMB 377 per gram [3][11] - The company’s total production costs for the Tongguan mining area decreased significantly from RMB 468 per gram to RMB 401 per gram due to scale efficiencies from acquisitions and increased production [11] - The projected net profits for 2026, 2027, and 2028 are estimated to be HKD 1.78 billion, HKD 2.06 billion, and HKD 2.50 billion respectively, reflecting growth rates of 114%, 16%, and 21% [4][29] Strategic Outlook - The company aims to enhance its research on mineralization patterns in Gansu and Tongguan, actively pursue mergers and acquisitions for growth, and maintain strategic cooperation with Zijin Mining [4][29]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Insights - In 2025, the company achieved total revenue of 3.43 billion, a year-on-year increase of 48.7%, and a net profit attributable to shareholders of 0.92 billion, up 238.5% year-on-year [6][10] - The company has significantly increased its paid user base by 59.5% to 289,000, while maintaining a stable refund rate of 22.9% [10] - The company is focusing on deepening AI application scenarios and enhancing its product matrix, which includes new business segments [10] Summary by Relevant Sections Financial Performance - The company reported total revenue of 3.43 billion in 2025, with a net profit of 0.92 billion, leading to a diluted ROE of 31.0%, an increase of 14.1 percentage points year-on-year [6][10] - The company's order revenue reached 3.96 billion, a year-on-year increase of 12.8%, with a return on investment (ROI) of 3.88 [10] User Growth and Retention - The number of paid users increased significantly, reaching 289,000, with a total order amount for main products showing a repurchase rate exceeding 60% [10] Cost Management and Profitability - The company increased its sales and R&D expenses to 1.41 billion and 0.36 billion respectively, while managing to reduce the expense ratios significantly, leading to improved profitability with gross and net margins of 82.2% and 26.9% respectively [10] Investment and Asset Management - The company's investment assets increased significantly to 2.09 billion, with a year-on-year growth of 214.9%, and achieved an investment income of 0.21 billion, reflecting a static annualized return of 15.5% [10] Strategic Focus - The company is committed to a dual-driven strategy of "investment research + technology," focusing on AI applications across various core scenarios [10] - The company has established strong barriers in customer education and traffic pool construction, with a positive long-term outlook on user conversion and penetration growth [10]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - In 2025, the company reported a revenue of 22.06 billion, a year-on-year decrease of 9.1%, and a net profit attributable to shareholders of 1.56 billion, down 7% [2][6]. - The dividend for 2025 is set at 1.66 HKD per share, reflecting a 3.1% increase, with a dividend yield of 5.9% [2][6]. - The operational business remains stable, with construction revenue declining, leading to an improved revenue structure and ongoing optimization of financial expenses [2][10]. Summary by Sections Revenue and Profitability - The core operational business showed stable growth, with water treatment services contributing 12.46 billion in revenue, a 1.8% increase year-on-year, and accounting for 4.93 billion in net profit, up 1.5% [10]. - The average contract price for water supply services in 2025 was approximately 2.13 CNY per ton, a slight decrease of 0.9% from 2024, while the average price for sewage and reclaimed water treatment services rose by 1.9% to 1.57 CNY per ton [10]. Business Transformation - The company is undergoing a business transformation, with construction service revenue declining by 40% to approximately 498 million, and BOT project revenue down 57% to 1.13 billion, primarily due to reduced new investments and project completions [10]. - The profit structure indicates that operational service revenue now accounts for 88% of total profit, an increase of 8 percentage points year-on-year, suggesting that fluctuations in construction business will have a manageable impact on profits [10]. Financial Performance - Financial expenses decreased significantly by 24.5% to 2.33 billion, attributed to ongoing debt structure optimization and effective cost control [10]. - Capital expenditures dropped sharply to 1.92 billion, a 53% decrease from 4.11 billion in 2024, indicating successful implementation of a light asset transformation strategy [10]. Future Outlook - The company is expected to achieve net profits attributable to shareholders of 1.51 billion, 1.57 billion, and 1.65 billion for the years 2026 to 2028, respectively [10]. - The anticipated dividend growth for 2026 is projected at 3%-5% based on 2025 figures, leading to a dividend yield of 6.1%-6.2% for the stock price as of March 25, 2026 [10].

Investment Rating - The report provides a positive outlook for Hansoh Pharmaceutical, indicating a strong performance in the second half of 2025 with revenue growth of 32% and net profit growth of 47%, exceeding market expectations by 2% and 10% respectively [4]. Core Insights - Hansoh Pharmaceutical is expected to experience significant growth in 2026, driven by the launch of innovative drugs and business development revenues. The year is characterized as a "harvest year" with multiple catalysts expected to enhance the company's pipeline value and profitability [4][7]. - Key clinical catalysts for 2026 include HS-20093 (B7H3 ADC), HS-20094 (GIP/GLP-1), and HS-10374 (TYK2), which are anticipated to provide critical clinical data and regulatory visibility [6][7]. Summary by Sections Financial Performance - In the second half of 2025, the oncology segment saw a sales increase of 49% to 5.4 billion yuan, while anti-infection products grew by 12% to 850 million yuan. However, sales in the central nervous system segment declined by 16% to 540 million yuan [5]. - Operating profit and net profit for the second half of 2025 increased by 76% and 47% respectively, reaching 22.7 billion yuan and 2.4 billion yuan [5]. Clinical Catalysts - HS-20093 is highlighted as a key catalyst in oncology, with pivotal Phase III clinical data expected to influence regulatory visibility and the value of the ADC platform. HS-20094 is noted for its potential impact on market sentiment, with detailed obesity data expected in 2026 [6]. - HS-10374 is considered an important indicator in immunology, with Phase III data for psoriasis serving as a test for the company's capabilities beyond oncology [6]. Company Overview - Hansoh Pharmaceutical is recognized as a leading R&D-driven innovative pharmaceutical company in China, focused on addressing unmet clinical needs and enhancing human health. As of June 30, 2025, the company had received approvals for seven innovative drugs and submitted four new drug applications [9].

Investment Rating - The investment rating for the company is maintained as "Buy" [1][10]. Core Views - The report highlights that the company's net interest income growth is improving, with a stable recovery in interest margins, which supports the resilience of its performance. The company is expected to maintain a high growth rate in non-interest income [6][7]. - The report projects a target price of HKD 52.79, reflecting a price-to-book (PB) ratio of 1.47 for 2026, indicating a valuation premium due to the stabilization of interest margins and the strengthening of its Southeast Asian business [10]. Financial Performance Summary - For the fiscal year 2025, the company is expected to achieve a revenue of HKD 77,019 million, representing an 8.09% year-on-year growth. The net profit attributable to shareholders is projected to be HKD 40,121 million, with a growth rate of 4.94% [5][17]. - The non-performing loan (NPL) ratio is expected to stabilize at 1.14% for 2025, with a provision coverage ratio of 96% by the end of the year [9][17]. - The report anticipates a dividend payout ratio of 56% for 2025, with a dividend yield of 5.24% [6][10]. Asset Quality and Cost Control - The total assets, loans, and deposits are projected to grow by 7.0%, 2.3%, and 8.1% respectively by the end of 2025, indicating a steady expansion of the asset-liability scale [7]. - The report notes that the company has effectively managed its cost of liabilities, with a decrease in the cost of interest-bearing liabilities and deposit costs, which supports the stability of interest margins [7][9]. Earnings Forecast - The earnings per share (EPS) for 2026 is projected to be HKD 4.13, with a price-to-earnings (PE) ratio of 9.82. The forecast for EPS shows a growth trajectory, with estimates of HKD 4.61 for 2027 and HKD 5.19 for 2028 [5][10][17]. - The report indicates that the company’s return on equity (ROE) is expected to improve from 11.51% in 2025 to 13.19% by 2028 [5][17].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 3.80 [4][6]. Core Insights - The company achieved a revenue of RMB 1.99 billion in 2025, representing a year-on-year growth of 9.2%, and a net profit of RMB 224 million, up 10.0% from the previous year [1][5]. - The pet business saw significant growth, with revenue increasing by 55.0% to RMB 220 million, and a compound annual growth rate (CAGR) of 42.3% from 2023 to 2025 [2]. - The acquisition of Hebei Kanda for up to RMB 450 million is expected to enhance the company's market position in Northern China and improve overall profitability [3]. - The company’s gross margin improved to 52.6%, a rise of 3.5 percentage points, driven by better product mix and supply chain efficiency [2]. - The company plans to maintain a high dividend payout ratio of 80%, with an expected dividend per share of HKD 0.148 for 2025 [1][4]. Financial Summary - For 2025, the company reported a net profit margin of 11.2%, consistent with the previous year [2]. - The projected net profit for FY26 and FY27 is expected to be RMB 250 million and RMB 280 million, respectively, indicating growth rates of 12.4% and 11.6% [4]. - The company’s cash balance at the end of 2025 was RMB 2.56 billion, supporting its acquisition strategy and dividend policy [1][5].

Investment Rating - The report assigns a "Buy" rating with a target price of HKD 1.91, representing a potential upside of 38.5% from the current price of HKD 1.38 [6]. Core Insights - The company is expected to benefit from a rebound in both meat and milk prices, leading to significant revenue growth and a turnaround in profitability by 2026. The projected net profits for 2026, 2027, and 2028 are estimated at HKD 5.8 billion, HKD 14.2 billion, and HKD 20.1 billion respectively [7]. - The company has demonstrated strong operational resilience despite a challenging industry environment, with a notable improvement in cash EBITDA, which grew by 2.6% to HKD 3.063 billion, and a gross margin increase of 1.4 percentage points to 27.4% [7]. - The report highlights the company's effective cost control measures, with the cost of milk sales per kilogram reduced to HKD 2.32, an 8.3% decrease year-on-year, and feed costs down by 9.2% to HKD 1.77 [7]. Financial Summary - Revenue for the fiscal year ending December 31, 2025, is reported at HKD 12.6 billion, a decline of 4.9% year-on-year. However, the company is expected to return to growth with projected revenues of HKD 13.5 billion in 2026, HKD 14.6 billion in 2027, and HKD 15.7 billion in 2028 [4][9]. - The net profit for 2025 is reported at a loss of HKD 12.04 billion, but a significant recovery is anticipated with a net profit of HKD 579 million in 2026 and HKD 1.42 billion in 2027 [4][9]. - The company's earnings per share (EPS) is projected to improve from a loss of HKD 0.14 in 2025 to a profit of HKD 0.07 in 2026, and further to HKD 0.18 in 2027 [4][9]. Industry Dynamics - The report indicates a significant restructuring in the supply-demand dynamics of the raw milk industry, with a continued decline in national dairy cow inventory expected to lead to potential supply shortages in 2026-2027 [7]. - The demand for domestic raw milk is increasing as imports of bulk powder have halved, and the growth in downstream processing capacity is gradually improving the supply-demand relationship [7]. - The report notes that the beef cycle is also showing signs of recovery, with the price of culled cows rebounding over 30% from its low in 2024, which is expected to provide additional revenue opportunities for the company [7].

Investment Rating - The report maintains a "Recommend" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [2][17]. Core Insights - The company reported a total revenue of $1.628 billion for 2025, a year-on-year decrease of 8.2%. The gross margin was 32.9%, down by 1.8 percentage points, and the net profit attributable to shareholders was $98 million, a decline of 13.2%. Adjusted net profit, excluding one-time gains from the sale of subsidiaries, was $78 million, reflecting a 42.2% year-on-year decrease [2][4]. - In the second half of 2025, revenue was $720 million, down 25.3% year-on-year, with net profit dropping to $2 million, a staggering 95.5% decline [2][4]. - The report highlights that the company faced significant pressure on profitability due to increased tariff costs and reduced economies of scale, particularly in the second half of 2025 [8]. Financial Performance Summary - **Revenue Forecast**: Projected revenues for 2026, 2027, and 2028 are $1.841 billion, $2.029 billion, and $2.195 billion, respectively, with expected growth rates of 13.1%, 10.2%, and 8.2% [4]. - **Net Profit Forecast**: Expected net profits for the same years are $116 million, $135 million, and $149 million, with growth rates of 18.5%, 16.8%, and 10.2% [4]. - **Earnings Per Share (EPS)**: Projected EPS for 2026, 2027, and 2028 are $0.23, $0.26, and $0.29, respectively [4]. - **Valuation Ratios**: The price-to-earnings (P/E) ratio is expected to decrease from 11 in 2025 to 7 by 2028, while the price-to-book (P/B) ratio is projected to decline from 1.1 to 0.9 over the same period [4]. Market Dynamics - The report notes that the company is expected to benefit from a recovery in U.S. demand and a stabilization of tariff impacts, which should drive revenue growth in 2026 [8]. - The introduction of new product categories and channel expansions, particularly for the high-end brand EGO, is anticipated to contribute to long-term growth [8].

Investment Rating - The investment rating for the company is "Buy" and it is maintained [6]. Core Insights - The company focuses on self-research and development to create cost advantages, resulting in an excellent price-performance ratio. It covers a price range of 50,000 to 200,000 CNY, with projected revenue of 64.73 billion CNY, a gross margin of 14.5%, and a net profit attributable to shareholders of 540 million CNY by 2025 [2][4]. - The domestic new car cycle is expected to drive continuous sales growth, while collaboration with Stellantis will facilitate asset-light international expansion, opening up global sales opportunities [2][7]. Summary by Sections Financial Performance - In Q4 2025, the company achieved sales of 201,000 units, a year-on-year increase of 63.2% and a quarter-on-quarter increase of 15.6%. Of these, 29,000 units were exported, accounting for 14.6% of total sales. Revenue for the quarter reached 21.03 billion CNY, up 56.3% year-on-year and 8.1% quarter-on-quarter, with an average revenue per vehicle of 105,000 CNY [7]. - The gross margin for Q4 2025 was 15.0%, an increase of 1.8 percentage points year-on-year and 0.5 percentage points quarter-on-quarter, driven by scale effects, cost reduction, product structure optimization, and other business income. The net profit attributable to shareholders was 360 million CNY, a year-on-year increase of 342.8% and a quarter-on-quarter increase of 138.9% [7]. Product and Market Strategy - The company covers various market segments with products priced between 50,000 and 200,000 CNY. The upcoming A and D series launches in 2026 are expected to further expand the product matrix and sales potential [7]. - The domestic channel strategy includes a "1+N" development model, with 950 sales outlets by the end of 2025, including 407 dedicated centers and 543 experience centers across 295 cities. Internationally, the company plans to export 67,000 vehicles in 2025, ranking among the top three in electric vehicle sales in 29 European countries [7]. Future Outlook - The company anticipates a strong new car cycle in the domestic market and a competitive edge through its exceptional price-performance ratio, which is expected to drive sales growth and improve profitability. The partnership with Stellantis is expected to leverage global resources for rapid and flexible international market entry [7]. - Projected net profits for 2026, 2027, and 2028 are 4.73 billion CNY, 9.22 billion CNY, and 11.74 billion CNY, respectively, with corresponding price-to-earnings ratios of 13.0X, 6.7X, and 5.2X [7].